Therapeutic strategies for rheumatoid arthritis (Q35140855)

6 August 2017

1 reference

title

Therapeutic strategies for rheumatoid arthritis. (English)

1 reference

6 August 2017

1 reference

1

Josef S Smolen

1 reference

6 August 2017

Günter Steiner

2

1 reference

6 August 2017

publication date

1 June 2003

1 reference

Nature Reviews Drug Discovery

6 August 2017

published in

1 reference

6 August 2017

volume

2

1 reference

6 August 2017

issue

6

1 reference

6 August 2017

page(s)

473-488

1 reference

The epidemiology of rheumatoid arthritis

6 August 2017

cites work

1 reference

Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures

31 March 2020

1 reference

An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline

31 March 2020

1 reference

The costs of rheumatoid arthritis: an international long-term view

31 March 2020

1 reference

Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity

31 March 2020

1 reference

Epidemiology and genetics of rheumatoid arthritis

31 March 2020

1 reference

HLA molecules, bacteria and autoimmunity

31 March 2020

1 reference

From reactive arthritis to rheumatoid arthritis

31 March 2020

1 reference

Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis

31 March 2020

1 reference

The treatment of rheumatoid arthritis and necrotizing vasculitis with penicillamine

31 March 2020

1 reference

Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial

31 March 2020

1 reference

Toll-like receptors: a family of pattern-recognition receptors in mammals

31 March 2020

1 reference

Toll receptors, CD14, and macrophage activation and deactivation by LPS.

31 March 2020

1 reference

Rheumatoid arthritis is more than cytokines: autoimmunity and rheumatoid arthritis

31 March 2020

1 reference

Autoantibodies in rheumatoid arthritis and their clinical significance

31 March 2020

1 reference

Characterization of autoreactive T cells to the autoantigens heterogeneous nuclear ribonucleoprotein A2 (RA33) and filaggrin in patients with rheumatoid arthritis

31 March 2020

1 reference

Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies

31 March 2020

1 reference

Whole-genome linkage analysis of rheumatoid arthritis susceptibility loci in 252 affected sibling pairs in the United Kingdom

31 March 2020

1 reference

Cytokine production by synovial T cells in rheumatoid arthritis

31 March 2020

1 reference

The role of T-lymphocytes and cytokines in rheumatoid arthritis

31 March 2020

1 reference

The balance of Th1/Th2 cytokines in rheumatoid arthritis

31 March 2020

1 reference

Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis

31 March 2020

1 reference

Dendritic cells (DCs) in rheumatoid arthritis (RA): progenitor cells and soluble factors contained in RA synovial fluid yield a subset of myeloid DCs that preferentially activate Th1 inflammatory-type responses

31 March 2020

1 reference

Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis

31 March 2020

1 reference

Macrophage activation by T cells: cognate and non-cognate signals

31 March 2020

1 reference

T-lymphocyte-fibroblast interactions

31 March 2020

1 reference

Cell contact between T cells and synovial fibroblasts causes induction of adhesion molecules and cytokines

31 March 2020

1 reference

Collagenase Production by Rheumatoid Synovial Cells: Stimulation by a Human Lymphocyte Factor

31 March 2020

1 reference

Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis

31 March 2020

1 reference

Interleukin-1 lymphocyte chemotactic activity in rheumatoid arthritis synovial fluid

31 March 2020

1 reference

Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum

31 March 2020

1 reference

Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis

31 March 2020

1 reference

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis

31 March 2020

1 reference

Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1

31 March 2020

1 reference

Role of interleukin 15 and interleukin 18 in inflammatory response

31 March 2020

1 reference

NF-kappaB at the crossroads of life and death

31 March 2020

1 reference

AP-1 as a regulator of cell life and death

31 March 2020

1 reference

Novel mechanistic concepts for the control of leukocyte transmigration: specialization of integrins, chemokines, and junctional molecules

31 March 2020

1 reference

Pannus and pannocytes. Alternative models of joint destruction in rheumatoid arthritis

31 March 2020

1 reference

Bone resorption by osteoclasts

31 March 2020

1 reference

Osteoclasts are essential for TNF-alpha-mediated joint destruction

31 March 2020

1 reference

Electron microscopic demonstration of immunoglobulin deposition in rheumatoid cartilage

31 March 2020

1 reference

Induction and suppression of collagen-induced arthritis is dependent on distinct fcgamma receptors

31 March 2020

1 reference

Stress hormones, proinflammatory and antiinflammatory cytokines, and autoimmunity

31 March 2020

1 reference

Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis

31 March 2020

1 reference

Effect of resumption of second line drugs in patients with rheumatoid arthritis that flared up after treatment discontinuation

31 March 2020

1 reference

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

31 March 2020

1 reference

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

31 March 2020

1 reference

The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses

31 March 2020

1 reference

The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial.

31 March 2020

1 reference

Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis

31 March 2020

1 reference

Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group

31 March 2020

1 reference

Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications

31 March 2020

1 reference

Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components

31 March 2020

1 reference

The efficacy and toxicity of combination therapy in rheumatoid arthritis. a meta-analysis

31 March 2020

1 reference

Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial

31 March 2020

1 reference

Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis

31 March 2020

1 reference

Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial

31 March 2020

1 reference

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

31 March 2020

1 reference

Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

31 March 2020

1 reference

Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis

31 March 2020

1 reference

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

31 March 2020

1 reference

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

31 March 2020

1 reference

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

31 March 2020

1 reference

Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein

31 March 2020

1 reference

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

31 March 2020

1 reference

Update on D2E7: a fully human anti-tumour necrosis factor alpha monoclonal antibody

31 March 2020

1 reference

Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002).

31 March 2020

1 reference

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

31 March 2020

1 reference

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

31 March 2020

1 reference

Interleukin-1 receptor antagonist: role in biology

31 March 2020

1 reference

Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice

31 March 2020

1 reference

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist

31 March 2020

1 reference

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial

31 March 2020

1 reference

A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores

31 March 2020

1 reference

Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis

31 March 2020

1 reference

Metalloproteases and inhibitors in arthritic diseases

31 March 2020

1 reference

ADAMTS: a novel family of extracellular matrix proteases

31 March 2020

1 reference

31 March 2020

1 reference

Development of matrix metalloproteinase inhibitors in cancer therapy.

31 March 2020

1 reference

Tissue inhibitors of metalloproteinases: evolution, structure and function

31 March 2020

1 reference

Adenovirus-based overexpression of tissue inhibitor of metalloproteinases 1 reduces tissue damage in the joints of tumor necrosis factor alpha transgenic mice

31 March 2020

1 reference

A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells

31 March 2020

1 reference

(E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2'-isobutyl-2'-(methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-alpha convertase

31 March 2020

1 reference

Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation.

31 March 2020

1 reference

A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling

31 March 2020

1 reference

Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures

31 March 2020

1 reference

A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes

31 March 2020

1 reference

ICE/Caspase-1 inhibitors as novel anti-inflammatory drugs

31 March 2020

1 reference

Interleukin-1 beta converting enzyme inhibition blocks progression of type II collagen-induced arthritis in mice

31 March 2020

1 reference

Relief of inflammatory pain in rats by local use of the selective P2X7 ATP receptor inhibitor, oxidized ATP.

31 March 2020

1 reference

Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response

31 March 2020

1 reference

Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity

31 March 2020

1 reference

Matrix metalloproteinases

31 March 2020

1 reference

AP-1 and NF-kappaB regulation in rheumatoid arthritis and murine collagen-induced arthritis

31 March 2020

1 reference

Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthr

31 March 2020

1 reference

Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase

31 March 2020

1 reference

The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy

31 March 2020

1 reference

Pyridinylimidazole based p38 MAP kinase inhibitors

31 March 2020

1 reference

RPR203494 a pyrimidine analogue of the p38 inhibitor RPR200765A with an improved in vitro potency

31 March 2020

1 reference

Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate

31 March 2020

1 reference

Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site

31 March 2020

1 reference

The non-diaryl heterocycle classes of p38 MAP kinase inhibitors

31 March 2020

1 reference

Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers.

31 March 2020

1 reference

Rescue of hearing, auditory hair cells, and neurons by CEP-1347/KT7515, an inhibitor of c-Jun N-terminal kinase activation

31 March 2020

1 reference

Inhibition of the c-Jun N-terminal kinase signaling pathway influences neurite outgrowth of spiral ganglion neurons in vitro

31 March 2020

1 reference

c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis

31 March 2020

1 reference

Inhibition of the MEK/ERK signaling pathway by the novel antimetastatic agent NAMI-A down regulates c-myc gene expression and endothelial cell proliferation

31 March 2020

1 reference

Downregulation of matrix metalloproteinase-9 and attenuation of edema via inhibition of ERK mitogen activated protein kinase in traumatic brain injury

31 March 2020

1 reference

Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer

31 March 2020

1 reference

The immunosuppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-kappaB.

31 March 2020

1 reference

Gliotoxin, an inhibitor of nuclear factor-kappa B, attenuates peptidoglycan-polysaccharide-induced colitis in rats

31 March 2020

1 reference

Pyrazolo[3,4-d]pyrimidines containing an extended 3-substituent as potent inhibitors of Lck -- a selectivity insight

31 March 2020

1 reference

Differential regulation of CD3- and CD28-induced IL-2 and IFN-gamma production by a novel tyrosine kinase inhibitor XR774 from Cladosporium cf. cladosporioides

31 March 2020

1 reference

Effects of geldanamycin, a heat-shock protein 90-binding agent, on T cell function and T cell nonreceptor protein tyrosine kinases

31 March 2020

1 reference

Inhibition of p56(lck) tyrosine kinase by isothiazolones

31 March 2020

1 reference

Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme

31 March 2020

1 reference

Genes on the X chromosome affect development of collagen-induced arthritis in mice

31 March 2020

1 reference

Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia

31 March 2020

1 reference

Bruton's tyrosine kinase links the B cell receptor to nuclear factor kappaB activation

31 March 2020

1 reference

Macrophage effector functions controlled by Bruton's tyrosine kinase are more crucial than the cytokine balance of T cell responses for microfilarial clearance

31 March 2020

1 reference

Phosphorylation of Bruton's tyrosine kinase by c-Abl.

31 March 2020

1 reference

B cell signaling. Introduction

31 March 2020

1 reference

Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial

31 March 2020

1 reference

Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study

31 March 2020

1 reference

Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis

31 March 2020

1 reference

Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage.

31 March 2020

1 reference

Interleukin 6 is required for the development of collagen-induced arthritis

31 March 2020

1 reference

Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial

31 March 2020

1 reference

The paradigm of IL-6: from basic science to medicine

31 March 2020

1 reference

Interleukin-2 receptor-directed therapies: antibody-or cytokine-based targeting molecules

31 March 2020

1 reference

Arginine butyrate increases the cytotoxicity of DAB(389)IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rbeta gene

31 March 2020

1 reference

Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis

31 March 2020

1 reference

Interleukin-2 diphtheria fusion protein (DAB486IL-2) in refractory rheumatoid arthritis. A double-blind, placebo-controlled trial with open-label extension.

31 March 2020

1 reference

Role of anti-interleukin-2 receptor antibodies in kidney transplantation

31 March 2020

1 reference

Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis

31 March 2020

1 reference

A proinflammatory role for IL-18 in rheumatoid arthritis

31 March 2020

1 reference

Reduced Incidence and Severity of Collagen-Induced Arthritis in Mice Lacking IL-18

31 March 2020

1 reference

Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis

31 March 2020

1 reference

Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium

31 March 2020

1 reference

The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model

31 March 2020

1 reference

CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis.

31 March 2020

1 reference

Chemokines, chemokine receptors and small-molecule antagonists: recent developments

31 March 2020

1 reference

Depletion of CCR5-expressing cells with bispecific antibodies and chemokine toxins: a new strategy in the treatment of chronic inflammatory diseases and HIV.

31 March 2020

1 reference

Neutralization of Vascular Endothelial Growth Factor Prevents Collagen-Induced Arthritis and Ameliorates Established Disease in Mice

31 March 2020

1 reference

31 March 2020

1 reference

VEGF-Trap: a VEGF blocker with potent antitumor effects

31 March 2020

1 reference

Retroviral gene therapy of collagen-induced arthritis by local delivery of IL-4.

31 March 2020

1 reference

Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis

31 March 2020

1 reference

Ciprofloxacin immunomodulation of experimental antiphospholipid syndrome associated with elevation of interleukin-3 and granulocyte-macrophage colony-stimulating factor expression

31 March 2020

1 reference

Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis

31 March 2020

1 reference

Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13

31 March 2020

1 reference

Reduction of inflammatory cytokines and prostaglandin E2 by IL-13 gene therapy in rheumatoid arthritis synovium

31 March 2020

1 reference

Recombinant human interferon gamma in the treatment of rheumatoid arthritis: double blind placebo controlled study

31 March 2020

1 reference

Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial

31 March 2020

1 reference

A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group

31 March 2020

1 reference

CD28/CTLA-4 and CD80/CD86 families: signaling and function

31 March 2020

1 reference

Treatment of autoimmunity by inhibition of T cell costimulation.

31 March 2020

1 reference

The CD40/CD154 receptor/ligand dyad

31 March 2020

1 reference

Activation and inhibition of lymphocytes by costimulation

31 March 2020

1 reference

Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells

31 March 2020

1 reference

Immunoadsorption for the treatment of rheumatoid arthritis: final results of a randomized trial. Prosorba Trial Investigators

31 March 2020

1 reference

31 March 2020

1 reference

Coordinate expression of activating Fc gamma receptors I and III and inhibiting Fc gamma receptor type II in the determination of joint inflammation and cartilage destruction during immune complex-mediated arthritis

31 March 2020

1 reference

Intercellular adhesion molecule-1 (ICAM-1) expression and cell signaling cascades

31 March 2020

1 reference

Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1

31 March 2020

1 reference

Adhesion events in angiogenesis.

31 March 2020

1 reference

Gelsolin deficiency blocks podosome assembly and produces increased bone mass and strength

31 March 2020

1 reference

Disease-modifying activity of SB 273005, an orally active, nonpeptide alphavbeta3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis

31 March 2020

1 reference

Anti-adhesion antibodies efalizumab, a humanized anti-CD11a monoclonal antibody

31 March 2020

1 reference

Natalizumab for active Crohn's disease

31 March 2020

1 reference

A controlled trial of natalizumab for relapsing multiple sclerosis

31 March 2020

1 reference

Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis

31 March 2020

1 reference

A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis

31 March 2020

1 reference

Biological aspects of signal transduction by cell adhesion receptors

31 March 2020

1 reference

Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site

31 March 2020

1 reference

Toll-like receptors as potential therapeutic targets for multiple diseases

31 March 2020

1 reference

Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium

31 March 2020

1 reference

Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis

31 March 2020

1 reference

Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin

31 March 2020

1 reference

Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand

31 March 2020

1 reference

TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis

31 March 2020

1 reference

The effect of a single dose of osteoprotegerin in postmenopausal women

31 March 2020

1 reference

Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell

31 March 2020

1 reference

Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial

31 March 2020

1 reference

The work of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT)

31 March 2020

1 reference

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials

31 March 2020

1 reference

Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group

31 March 2020

1 reference

Local production of complement proteins in rheumatoid arthritis synovium

31 March 2020

1 reference

7 January 2021

Is NF-kappaB a useful therapeutic target in rheumatoid arthritis?

1 reference

7 January 2021

Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]

1 reference

7 January 2021

Endotoxin-induced serum factor that stimulates gamma interferon production

1 reference

7 January 2021

Identifiers

DOI

10.1038/NRD1109

1 reference

6 August 2017

1 reference